Viola Cogliati
Monza, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study.
Journal: ESMO real world data and digital oncology
Published: April 03, 2026
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer.
Journal: Biomedicines
Published: December 08, 2023
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells.
Journal: International journal of molecular sciences
Published: August 06, 2023
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows.
Journal: Journal of clinical medicine
Published: July 11, 2022
Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything.
Journal: Cancers
Published: June 20, 2022
How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story.
Journal: Life (Basel, Switzerland)
Published: January 18, 2022
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Journal: Breast cancer research and treatment
Published: August 13, 2021
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects.
Journal: Cancers
Published: September 28, 2020
Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse.
Journal: Future oncology (London, England)
Published: August 09, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026